Athena Athena

X
[{"orgOrder":0,"company":"Advanced BioDesign","sponsor":"Xerys Funds","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"Advanced BioDesign Raises Additional \u20ac9 Million From Xerys Funds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Advanced BioDesign

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Advanced BioDesign will finalise its preclinical studies and submit a clinical trial authorization to start clinical phase I in AML in early 2021.

            Lead Product(s): ABD-3001

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Xerys Funds

            Deal Size: $9.8 million Upfront Cash: Undisclosed

            Deal Type: Funding February 26, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY